Fluid Imaging Headlines

Integrate Advanced Biomarker Assessment of Neurodegeneration & Neuroinflammation to More Sensitively Translate CNS Drugs

Welcome to the Fluid & Imaging Biomarkers in Neuroscience Summit

The First Industry Forum for Translational Experts, Neuroscience Drug Sponsors & Biomarker Technology Developers to Transform Earlier Assessment of AD, PD, ALS & MS

Development and integration of validated, inexpensive, non-invasive, and reliable fluid and imaging biomarkers are critical to advance neurodegenerative and neuro-immunological drug candidates through clinical trials.

Built to provide cutting-edge insights across emerging biomarker technologies and address the current translational bottleneck hindering your pipeline’s success: the inaugural Fluid & Imaging Biomarkers in Neuroscience Summit is an unrivaled new opportunity to evaluate the latest biomarker research across AD, PD, MS & ALS, in one highly focused forum.

Unite with translational experts and biomarker specialists from the likes of Biogen, Eli Lilly, and Janssen to engage in forward-thinking discussions to meaningfully advance biomarker assessments of neurodegenerative and neuroinflammatory disease-modifying therapeutics.

”This meeting is a great opportunity to come together and discuss how we can support the clinical research moving forward with biomarkers in neurodegeneration, I very much look forward to the event!”

Kira Holmstrom Head of Biomarker Research Herantis Pharma

“This is an incredible opportunity to gain insight from academic and pharma leaders in the rapidly advancing field of fluid and imaging biomarkers in neuroscience”

Olga Kahn, Biomarker Scientist, Alector

“This is a great opportunity for researchers, biomarker developers and Pharma to connect and discuss fluid and imaging biomarkers in Neuroscience.”

Fan Liao Principal Research Scientist AbbVie

Other Events in the World CNS Series: